About: Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection
Creator	Danzi, Gian Di Tano, Giuseppe Gherbesi, Elisa Loffi, Marco Moschini, Luigi Regazzoni, Valentina
source	Medline; PMC
abstract	INTRODUCTION: Most of the drugs associations that have been used to treat patients with SARS-CoV-2 infection increase the risk of prolongation of the corrected QT interval (QTc). OBJECTIVE: To evaluate the effects of an association therapy of hydroxychloroquine (HY) plus ritonavir/darunavir (RD) or azithromycin (AZ) on QTc intervals. METHODS: At the beginning of COVID-19 pandemic patients admitted to our hospital were treated with the empiric association of HY/RD; one week later the therapeutic protocol was modified with the combination of HY/AZ. Patients underwent an ECG at baseline, then 3 and 7 days after starting therapy. We prospectively enrolled 113 patients (61 in the HY/RD group-52 in the HY/AZ group). RESULTS: A significant increase in median QTc was reported after seven days of therapy in both groups: from 438 to 452 ms in HY/RD patients; from 433 to 440 ms in HY/AZ patients (p = 0.001 for both). 23 patients (21.2%) had a QTc > 500 ms at 7 days. The risk of developing a QTc > 500 ms was greater in patients with prolonged baseline QTc values (≥ 440 ms for female and ≥ 460 ms for male patients) (OR 7.10 (95% IC 1.88–26.81); p = 0.004) and in patients with an increase in the QTc > 40 ms 3 days after onset of treatment (OR 30.15 (95% IC 6.96–130.55); p = 0.001). One patient per group suffered a malignant ventricular arrhythmia. CONCLUSION: Hydroxychloroquine with both ritonavir/darunavir or azithromycin therapy significantly increased the QTc-interval at 7 days. The risk of developing malignant arrhythmias remained relatively low when these drugs were administered for a limited period of time.
has issue date	2020-07-16(xsd:dateTime)
bibo:doi	10.1007/s00380-020-01671-4
bibo:pmid	32676695
has license	no-cc
sha1sum (hex)	d53508d43264f59007fd5e4aa8b4af026edf0bfe
schema:url	https://doi.org/10.1007/s00380-020-01671-4
resource representing a document's title	Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection
has PubMed Central identifier	PMC7364290
has PubMed identifier	32676695
schema:publication	Heart Vessels
resource representing a document's body	covid:d53508d43264f59007fd5e4aa8b4af026edf0bfe#body_text
is schema:about of	named entity 'female' named entity 'protocol' named entity 'QT interval' named entity 'COVID-19 PANDEMIC' named entity 'ONE WEEK' named entity 'OBJECTIVE' named entity 'ECG' named entity 'COMBINATION' named entity 'VALUES' named entity 'ADMITTED TO' named entity 'SEVEN' named entity 'patients' named entity 'male' named entity 'Hydroxychloroquine' named entity 'empiric' named entity 'ventricular arrhythmia' named entity 'QTc' named entity 'treated' named entity 'developing' named entity 'remained' named entity 'QTc prolongation' named entity 'laboratory tests' named entity 'ritonavir' named entity 'arrhythmogenic' named entity 'estimated glomerular filtration rate' named entity 'QTc interval' named entity 'associations' named entity 'therapy' named entity 'COVID-19' named entity 'ECG' named entity 'QTc' named entity 'azithromycin' named entity 'QTc' named entity 'QTc' named entity 'malignant' named entity 'arrhythmias' named entity 'ritonavir' named entity 'azithromycin' named entity 'SARS-CoV-2' named entity 'hydroxychloroquine' named entity 'life-threatening' named entity 'ECG' named entity 'study population' named entity 'SPSS' named entity 'ECG' named entity 'hydroxychloroquine' named entity 'QTc' named entity 'pneumonia' named entity 'QTc' named entity 'malignant' named entity 'statistically significant' named entity 'TdP' named entity 'regression analysis' named entity 'study population' named entity 'antiretroviral drugs' named entity 'cardiac arrhythmias' named entity 'TdP' named entity 'arrhythmias' named entity 'QTc interval' named entity 'estimated glomerular filtration rate' named entity 'darunavir' named entity 'QTc prolongation' named entity '12-lead ECG' named entity 'QTc' named entity 'QTc' named entity 'QTc' named entity 'arrhythmias' named entity 'Darunavir' named entity 'QTc' named entity 'COVID-19' named entity 'viral load' named entity 'QTc' named entity 'bradycardia' named entity 'QTc' named entity 'ventricular arrhythmias' named entity 'acute respiratory distress syndrome'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software